Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046201) METHODS AND COMPOSITIONS TO INHIBIT ADVERSE EFFECTS ASSOCIATED WITH VACCINATIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046201 International Application No.: PCT/US2018/048167
Publication Date: 07.03.2019 International Filing Date: 27.08.2018
IPC:
G06F 19/00 (2018.01)
G PHYSICS
06
COMPUTING; CALCULATING; COUNTING
F
ELECTRIC DIGITAL DATA PROCESSING
19
Digital computing or data processing equipment or methods, specially adapted for specific applications
Applicants:
SEN-JAM PHARMACEUTICAL LLC [US/US]; 233 Wall Street, #130 Huntington, NY 11743, US
Inventors:
IVERSEN, Jacqueline; US
DAHL, Thomas, A.; US
Agent:
HENNEBERGER, Glenn, T.; US
BENNETT, Anthony, E.; US
HARRINGTON, James, F.; US
SIPOS, Susan, A.; US
ZUSCHLAG, Steven, T.; US
Priority Data:
62/552,02930.08.2017US
Title (EN) METHODS AND COMPOSITIONS TO INHIBIT ADVERSE EFFECTS ASSOCIATED WITH VACCINATIONS
(FR) PROCÉDÉS ET COMPOSITIONS POUR INHIBER LES EFFETS INDÉSIRABLES ASSOCIÉS À LA VACCINATION
Abstract:
(EN) The invention relates to methods of inhibiting side effects associated with vaccination in a human subject in need thereof. The method comprises administering an effective amount of a pharmaceutical composition to the subject before the subject is vaccinated, wherein the pharmaceutical composition comprises: a) a non-steroidal anti-inflammatory drug (NSAID); and b) a co-agent selected from the group consisting of: fexofenadine, ketotifen, desloratadine and cetirizine and combinations thereof.
(FR) La présente invention concerne des procédés d'inhibition des effets indésirables associés à la vaccination chez un sujet humain qui en a besoin. Le procédé comprend l'administration d'une quantité efficace d'une composition pharmaceutique au sujet avant que le sujet soit vacciné, la composition pharmaceutique comprenant : a) un médicament anti-inflammatoire non stéroïdien (AINS); et b) un co-agent choisi dans le groupe constitué par : la fexofénadine, la kétotifène, la desloratadine et la cétirizine et des combinaisons de ceux-ci.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)